TDRP
gene geneOn this page
Also known as INM01TDRP1TDRP2
Summary
TDRP (testis development related protein, HGNC:26951) is a protein-coding gene on chromosome 8p23.3, encoding Testis development-related protein (Q86YL5). Contributes to normal sperm motility, but not essential for male fertility.
Acts upstream of or within spermatogenesis. Located in cytosol and nucleus.
Source: NCBI Gene 157695 — RefSeq curated summary.
At a glance
- GWAS associations: 4
- Clinical variants (ClinVar): 53 total — 1 pathogenic
- MANE Select transcript:
NM_001384899
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:26951 |
| Approved symbol | TDRP |
| Name | testis development related protein |
| Location | 8p23.3 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | INM01, TDRP1, TDRP2 |
| Ensembl gene | ENSG00000180190 |
| Ensembl biotype | protein_coding |
| OMIM | 619049 |
| Entrez | 157695 |
Gene structure
Transcript identifiers
Ensembl transcripts: 3 — 2 protein_coding, 1 protein_coding_CDS_not_defined
ENST00000324079, ENST00000523656, ENST00000524229
RefSeq mRNA: 3 — MANE Select: NM_001384899
NM_001256113, NM_001384899, NM_175075
CCDS: CCDS47759, CCDS59090
Canonical transcript exons
ENST00000324079 — 3 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001226847 | 489946 | 492744 |
| ENSE00002114651 | 544650 | 544834 |
| ENSE00003593946 | 494494 | 494597 |
Expression profiles
Bgee: expression breadth ubiquitous, 233 present calls, max score 97.75.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 4.2529 / max 77.5792, expressed in 1022 samples.
FANTOM5 promoters (1 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 91548 | 4.2529 | 1022 |
Top tissues by expression
251 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| secondary oocyte | CL:0000655 | 97.75 | gold quality |
| oocyte | CL:0000023 | 96.48 | gold quality |
| right uterine tube | UBERON:0001302 | 95.38 | gold quality |
| oviduct epithelium | UBERON:0004804 | 92.94 | gold quality |
| endothelial cell | CL:0000115 | 92.72 | gold quality |
| right testis | UBERON:0004534 | 91.95 | gold quality |
| Brodmann (1909) area 23 | UBERON:0013554 | 91.60 | gold quality |
| left testis | UBERON:0004533 | 91.58 | gold quality |
| epithelial cell of pancreas | CL:0000083 | 91.56 | gold quality |
| placenta | UBERON:0001987 | 90.64 | gold quality |
| left lobe of thyroid gland | UBERON:0001120 | 89.35 | gold quality |
| thyroid gland | UBERON:0002046 | 89.27 | gold quality |
| testis | UBERON:0000473 | 89.12 | gold quality |
| middle temporal gyrus | UBERON:0002771 | 89.05 | gold quality |
| amniotic fluid | UBERON:0000173 | 89.02 | gold quality |
| right lobe of thyroid gland | UBERON:0001119 | 89.01 | gold quality |
| germinal epithelium of ovary | UBERON:0001304 | 88.56 | gold quality |
| pigmented layer of retina | UBERON:0001782 | 87.88 | gold quality |
| visceral pleura | UBERON:0002401 | 87.37 | gold quality |
| metanephros cortex | UBERON:0010533 | 87.29 | gold quality |
| primary visual cortex | UBERON:0002436 | 86.63 | gold quality |
| caudate nucleus | UBERON:0001873 | 86.52 | gold quality |
| left ovary | UBERON:0002119 | 86.43 | gold quality |
| nucleus accumbens | UBERON:0001882 | 86.35 | gold quality |
| adenohypophysis | UBERON:0002196 | 86.13 | gold quality |
| fallopian tube | UBERON:0003889 | 86.06 | gold quality |
| pituitary gland | UBERON:0000007 | 85.97 | gold quality |
| cortical plate | UBERON:0005343 | 85.55 | gold quality |
| right ovary | UBERON:0002118 | 85.21 | gold quality |
| ganglionic eminence | UBERON:0004023 | 85.17 | gold quality |
Single-cell (SCXA)
Detected in 3 experiment(s), a significant marker in 3.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-MTAB-3929 | yes | 95.41 |
| E-MTAB-9388 | yes | 11.32 |
| E-ANND-3 | no | 0.00 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
121 targeting TDRP, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-6867-5P | 100.00 | 82.21 | 3464 |
| HSA-MIR-3646 | 100.00 | 73.56 | 5283 |
| HSA-MIR-30A-5P | 100.00 | 76.31 | 3233 |
| HSA-MIR-30B-5P | 100.00 | 76.29 | 3248 |
| HSA-MIR-30C-5P | 100.00 | 76.29 | 3248 |
| HSA-MIR-30D-5P | 100.00 | 76.32 | 3233 |
| HSA-MIR-30E-5P | 100.00 | 76.32 | 3242 |
| HSA-MIR-3925-3P | 100.00 | 69.95 | 1237 |
| HSA-MIR-150-5P | 99.99 | 66.69 | 1976 |
| HSA-MIR-548C-3P | 99.99 | 74.01 | 7587 |
| HSA-MIR-5696 | 99.98 | 72.36 | 4487 |
| HSA-MIR-12136 | 99.98 | 72.81 | 5713 |
| HSA-MIR-4482-3P | 99.98 | 72.50 | 3147 |
| HSA-MIR-548N | 99.98 | 71.94 | 4170 |
| HSA-MIR-4803 | 99.98 | 71.99 | 3117 |
| HSA-MIR-4775 | 99.98 | 75.00 | 6394 |
| HSA-MIR-302C-5P | 99.97 | 72.56 | 3642 |
| HSA-MIR-607 | 99.97 | 73.62 | 5593 |
| HSA-MIR-3658 | 99.96 | 73.87 | 4379 |
| HSA-MIR-548AJ-3P | 99.96 | 73.38 | 5345 |
| HSA-MIR-548X-3P | 99.96 | 73.38 | 5345 |
| HSA-MIR-548AA | 99.96 | 70.64 | 3753 |
| HSA-MIR-548AP-3P | 99.96 | 70.64 | 3753 |
| HSA-MIR-548T-3P | 99.96 | 70.64 | 3753 |
| HSA-MIR-495-3P | 99.96 | 72.81 | 4197 |
| HSA-MIR-5688 | 99.96 | 73.23 | 4504 |
| HSA-MIR-545-3P | 99.95 | 70.74 | 2783 |
| HSA-MIR-128-3P | 99.95 | 71.17 | 2484 |
| HSA-MIR-216A-3P | 99.95 | 71.19 | 2505 |
| HSA-MIR-3910 | 99.95 | 71.13 | 2227 |
Literature-anchored findings (GeneRIF, showing 3)
- These current data demonstrated that as a nuclear factor, TDRP1 might play an important role in spermatogenesis. (PMID:20170638)
- Single nucleotide polymorphisms on genetic loci SOD2, MBP and C8orf42were not found significantly associated with advanced age-related macular degeneration in a Chinese cohort (PMID:24667176)
- TDRP expression in healthy human palatal mucosa is strongly negatively correlated with serum cotinine levels (PMID:31682009)
Cross-species orthologs
3 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | si:ch211-225h24.2 | ENSDARG00000104936 |
| mus_musculus | Tdrp | ENSMUSG00000050052 |
| rattus_norvegicus | Tdrp | ENSRNOG00000027245 |
Protein
Protein identifiers
Testis development-related protein — Q86YL5 (reviewed: Q86YL5)
Alternative names: Protein INM01
All UniProt accessions (1): Q86YL5
UniProt curated annotations — full annotation on UniProt →
Function. Contributes to normal sperm motility, but not essential for male fertility.
Subunit / interactions. Interacts with PRM2.
Subcellular location. Nucleus. Cytoplasm.
Tissue specificity. Expressed in spermatogenic cells, especially in spermatocytes (at protein level).
Polymorphism. The poly-Ala region seems to be polymorphic and the number of Ala varies between 4 and 6.
Similarity. Belongs to the TDRP family.
Isoforms (2)
| UniProt ID | Names | Canonical? |
|---|---|---|
| Q86YL5-1 | 1, TDRP1 | yes |
| Q86YL5-2 | 2, TDRP2 |
RefSeq proteins (3): NP_001243042, NP_001371828, NP_778250 (=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR031399 | TDRP | Family |
Pfam: PF15683
UniProt features (4 total): region of interest 2, chain 1, splice variant 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q86YL5-F1 | 60.41 | 0.01 |
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 176 (showing top):
RORA1_01, GOBP_MALE_GAMETE_GENERATION, HOWLIN_PUBERTAL_MAMMARY_GLAND, GOBP_DEVELOPMENTAL_PROCESS_INVOLVED_IN_REPRODUCTION, CUI_TCF21_TARGETS_2_DN, GAVIN_FOXP3_TARGETS_CLUSTER_P3, ZHOU_INFLAMMATORY_RESPONSE_LIVE_UP, BENPORATH_ES_1, MEISSNER_NPC_HCP_WITH_H3K4ME2_AND_H3K27ME3, RORA2_01, MIKKELSEN_NPC_HCP_WITH_H3K27ME3, LI_INDUCED_T_TO_NATURAL_KILLER_DN, IWANAGA_CARCINOGENESIS_BY_KRAS_PTEN_UP, GSE13522_CTRL_VS_T_CRUZI_BRAZIL_STRAIN_INF_SKIN_DN, GSE13522_CTRL_VS_T_CRUZI_Y_STRAIN_INF_SKIN_IFNAR_KO_UP
GO Biological Process (1): spermatogenesis (GO:0007283)
GO Molecular Function (0):
GO Cellular Component (4): nucleus (GO:0005634), cytoplasm (GO:0005737), mitochondrion (GO:0005739), cytosol (GO:0005829)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| intracellular membrane-bounded organelle | 2 |
| cellular anatomical structure | 2 |
| cytoplasm | 2 |
| developmental process involved in reproduction | 1 |
| male gamete generation | 1 |
| intracellular anatomical structure | 1 |
Protein interactions and networks
STRING
334 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| TDRP | FBXO25 | Q8TCJ0 | 696 |
| TDRP | ZNF596 | Q8TC21 | 645 |
| TDRP | FBXO38 | Q6PIJ6 | 616 |
| TDRP | PRM2 | P04554 | 559 |
| TDRP | ERICH1 | Q86X53 | 547 |
| TDRP | SMOC2 | Q9H3U7 | 534 |
| TDRP | GPCPD1 | Q9NPB8 | 455 |
| TDRP | LINC03040 | Q8N319 | 434 |
| TDRP | KBTBD11 | O94819 | 399 |
| TDRP | CCDC148 | Q8NFR7 | 394 |
| TDRP | EPDR1 | Q9UM22 | 393 |
| TDRP | OR4F21 | O95013 | 380 |
| TDRP | LACC1 | Q8IV20 | 372 |
| TDRP | TRAT1 | Q6PIZ9 | 368 |
| TDRP | ARHGEF10 | O15013 | 368 |
IntAct
2 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| CETN1 | SFI1 | psi-mi:“MI:0914”(association) | 0.640 |
BioGRID (9): TDRP (Affinity Capture-MS), TDRP (Proximity Label-MS), TDRP (Proximity Label-MS), TDRP (Proximity Label-MS), TDRP (Proximity Label-MS), TDRP (Affinity Capture-MS), TDRP (Protein-peptide), TDRP (Affinity Capture-MS), TDRP (Proximity Label-MS)
ESM2 similar proteins: A0A1B0GTI1, A2BIL8, A5PKK9, C5DY61, E2QSX5, E7F555, O35147, O43151, P11805, P19416, P24940, P27579, Q06616, Q17QE3, Q1LZE2, Q1RMQ5, Q1T763, Q28CW2, Q2HR82, Q2TBN9, Q3B8E9, Q3ZBS1, Q567C6, Q5RDK8, Q62417, Q68FW2, Q6AY26, Q6DFB0, Q6P6I6, Q6PKN7, Q80U49, Q86YL5, Q8C3W1, Q8QVM1, Q8VEB3, Q8VI59, Q96FT9, Q96GV9, Q96GY3, Q99618
Diamond homologs: Q498E2, Q5I019, Q86YL5, Q8C5P7
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
53 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 1 |
| Likely pathogenic | 0 |
| Uncertain significance | 48 |
| Likely benign | 3 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (1)
| Variant ID | HGVS | Classification |
|---|---|---|
| 1328106 | GRCh37/hg19 8p23.3-23.2(chr8:162190-4698813)x1 | Pathogenic |
SpliceAI
1300 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 8:492745:C:CC | acceptor_gain | 1.0000 |
| 8:494489:CTTAC:C | donor_loss | 1.0000 |
| 8:494490:TTACC:T | donor_loss | 1.0000 |
| 8:494491:TA:T | donor_loss | 1.0000 |
| 8:494492:A:AC | donor_gain | 1.0000 |
| 8:494492:AC:A | donor_gain | 1.0000 |
| 8:494493:C:CC | donor_gain | 1.0000 |
| 8:494493:CC:C | donor_gain | 1.0000 |
| 8:494594:GAAC:G | acceptor_gain | 1.0000 |
| 8:494596:AC:A | acceptor_gain | 1.0000 |
| 8:494597:CC:C | acceptor_gain | 1.0000 |
| 8:494598:C:CC | acceptor_gain | 1.0000 |
| 8:492740:TAGTT:T | acceptor_gain | 0.9900 |
| 8:492742:GTT:G | acceptor_gain | 0.9900 |
| 8:492742:GTTC:G | acceptor_loss | 0.9900 |
| 8:492743:TT:T | acceptor_gain | 0.9900 |
| 8:492744:TCTA:T | acceptor_loss | 0.9900 |
| 8:492745:C:CG | acceptor_loss | 0.9900 |
| 8:492746:T:G | acceptor_loss | 0.9900 |
| 8:494492:ACC:A | donor_gain | 0.9900 |
| 8:494493:CCC:C | donor_gain | 0.9900 |
| 8:494493:CCCT:C | donor_gain | 0.9900 |
| 8:494593:TGAAC:T | acceptor_gain | 0.9900 |
| 8:494595:AAC:A | acceptor_gain | 0.9900 |
| 8:494598:C:T | acceptor_gain | 0.9900 |
| 8:544145:A:C | donor_gain | 0.9900 |
| 8:544175:AGTGT:A | donor_gain | 0.9900 |
| 8:544645:CTCA:C | donor_loss | 0.9900 |
| 8:544647:CA:C | donor_loss | 0.9900 |
| 8:544649:C:A | donor_loss | 0.9900 |
AlphaMissense
1191 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 8:492632:A:G | W109R | 0.990 |
| 8:492632:A:T | W109R | 0.990 |
| 8:492690:C:A | W89C | 0.988 |
| 8:492690:C:G | W89C | 0.988 |
| 8:492692:A:G | W89R | 0.988 |
| 8:492692:A:T | W89R | 0.988 |
| 8:492630:C:A | W109C | 0.987 |
| 8:492630:C:G | W109C | 0.987 |
| 8:494573:A:G | W45R | 0.977 |
| 8:494573:A:T | W45R | 0.977 |
| 8:492693:A:C | F88L | 0.975 |
| 8:492693:A:T | F88L | 0.975 |
| 8:492695:A:G | F88L | 0.975 |
| 8:494571:C:A | W45C | 0.975 |
| 8:494571:C:G | W45C | 0.975 |
| 8:492694:A:G | F88S | 0.973 |
| 8:544754:A:G | W2R | 0.973 |
| 8:544754:A:T | W2R | 0.973 |
| 8:544752:C:A | W2C | 0.970 |
| 8:544752:C:G | W2C | 0.970 |
| 8:492485:A:G | W158R | 0.967 |
| 8:492485:A:T | W158R | 0.967 |
| 8:492635:C:G | G108R | 0.951 |
| 8:492483:C:A | W158C | 0.949 |
| 8:492483:C:G | W158C | 0.949 |
| 8:492631:C:G | W109S | 0.949 |
| 8:492691:C:G | W89S | 0.949 |
| 8:494569:T:A | K46I | 0.949 |
| 8:492672:T:A | K95N | 0.946 |
| 8:492672:T:G | K95N | 0.946 |
dbSNP variants (sampled 300 via entrez): RS1000007205 (8:512861 A>C), RS1000016748 (8:535845 C>T), RS1000043496 (8:490490 C>T), RS1000072190 (8:490830 T>A,C), RS1000078600 (8:512969 C>T), RS1000084238 (8:532094 G>T), RS1000127570 (8:525876 G>C), RS1000147348 (8:522960 T>C), RS1000196698 (8:497407 G>C), RS1000212146 (8:504238 A>C,G,T), RS1000242690 (8:523093 C>T), RS1000269823 (8:493779 G>A,C), RS1000270565 (8:500849 G>C), RS1000310259 (8:547643 A>G), RS1000326122 (8:543703 T>C)
Disease associations
OMIM: gene MIM:619049 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
4 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST001091_1 | Bilirubin levels | 5.000000e-07 |
| GCST006622_21 | Neonatal cytokine/chemokine levels (fetal genetic effect) | 2.000000e-09 |
| GCST008513_14 | Health literacy | 2.000000e-06 |
| GCST008513_15 | Health literacy | 3.000000e-07 |
EFO canonical traits (5, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0004570 | bilirubin measurement |
| EFO:0004747 | protein measurement |
| EFO:0007959 | fetal genotype effect measurement |
| EFO:0008184 | interleukin 4 measurement |
| EFO:0010104 | health literacy measurement |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
33 total (human), top 30 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Valproic Acid | increases expression, increases methylation, affects cotreatment | 7 |
| trichostatin A | affects cotreatment, increases expression | 3 |
| sodium arsenite | decreases expression, affects cotreatment, increases abundance, increases expression | 3 |
| methylmercuric chloride | decreases expression | 2 |
| mercuric bromide | increases expression, affects cotreatment | 2 |
| entinostat | increases expression, affects cotreatment | 2 |
| Panobinostat | affects cotreatment, increases expression | 2 |
| Nickel | decreases expression | 2 |
| Phenylmercuric Acetate | affects cotreatment, increases expression | 2 |
| dicrotophos | decreases expression | 1 |
| triphenyl phosphate | affects expression | 1 |
| bisphenol A | affects cotreatment, increases methylation | 1 |
| manganese chloride | increases abundance, increases expression, affects cotreatment | 1 |
| aflatoxin B2 | decreases methylation | 1 |
| 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | increases expression, affects cotreatment | 1 |
| 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide | decreases reaction, decreases expression | 1 |
| dorsomorphin | affects cotreatment, increases expression | 1 |
| bisphenol S | affects cotreatment, decreases methylation | 1 |
| Temozolomide | affects response to substance | 1 |
| Fulvestrant | decreases methylation, affects cotreatment, increases methylation | 1 |
| Arsenic | affects cotreatment, increases abundance, increases expression | 1 |
| Vehicle Emissions | decreases expression, decreases reaction | 1 |
| Benzo(a)pyrene | affects methylation | 1 |
| Carmustine | affects response to substance | 1 |
| Malathion | decreases expression | 1 |
| Manganese | increases abundance, increases expression, affects cotreatment | 1 |
| Niclosamide | increases expression | 1 |
| Thiram | decreases expression | 1 |
| Tobacco Smoke Pollution | decreases expression | 1 |
| Aflatoxin B1 | increases methylation | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.